The negative tuberculin test. Tuberculin, HIV, and anergy panels.

Pesanti, Edward L.

doi:10.1164/ajrccm.149.6.7710481

Cited by 56 publications

(31 citation statements)

References 201 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cells were stimulated for 16-20 h (under 5% carbon dioxide at 37uC) with media (nil control), phytohaemagglutinin (mitogen-positive control) or the specific antigens (6-kDa early secretory antigenic target and culture filtrate protein 10, in separate wells). The IFN-c released by single cells was quantified using ELISPOT technology [4]. Results are presented as the number of spot-forming cells (SFCs).…”

Section: T-spottbmentioning

confidence: 99%

“…Unfortunately, the sensitivity of the current method of determining infection, the tuberculin skin test (TST), is known to be low [3,4]. Therefore, it was desirable to examine whether the new interferon (IFN)-c-based tests for TB infection might give useful additional information, as the performance of these tests in immunosuppressed haematology patients is currently unknown [5].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients: Table 1—

Piana¹,

et al. 2006

View full text Add to dashboard Cite

The aim of this study was to compare the performance of the T-SPOT.TB TM test, a Tcell-based test, with the tuberculin skin test (TST) in the diagnosis of latent tuberculosis (TB) infection.The study was carried out in 138 immunosuppressed haematology patients who had been nosocomially exposed to a case of smear-positive TB.Overall, 44.2% of the contacts were positive by T-SPOT.TB TM test, and 17.4% by TST (concordance 67.8%). The apparent prevalence of infection fell from 25.9 to 14.5% with the TST with increasing immunosuppression, although this difference was not significant. In contrast, the apparent prevalence of infection with the T-SPOT.TB TM test was unaffected at 44.6 and 44.3%, respectively. The T-SPOT.TB TM test had an overall indeterminate rate of 4.3%, and this was also unaffected by the level of immunosuppression. This study suggests that the T-SPOT.TB TM test maintains its sensitivity and performance in immunocompromised patients, identifying a large number of truly infected patients anergic to the tuberculin skin test.

show abstract

Section: T-spottbmentioning

confidence: 99%

mentioning

confidence: 99%

Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients: Table 1—

Piana¹,

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Similarly, patients with renal failure or malnutrition, concurrent viral illness such as infectious mononucleosis or measles, and recent live-virus vaccination (such as for measles or mumps) may have temporary anergy and a falsenegative tuberculin test result. 20 The 2 main causes of false-positive results are infection with nontuberculous mycobacteria and BCG vaccination. Many nontuberculous mycobacteria occur in the soil and water in tropical and subtropical climates, 21,22 and sensitivity to these bacteria is common among people living in these areas and may lead to false-positive tuberculin test results through cross-reactivity.…”

Section: Preventing Transmission Of Tuberculosis (Tb)mentioning

confidence: 99%

“…HIVinfected patients who are tuberculin negative, particularly if their CD4 count is less than 500 × 10 9 /L, may be considered for further assessment, including chest radiography and even preventive therapy, given the high rate of false-negative tuberculin tests in this group. [18][19][20] Screening in high-risk settings, such as acute care hospitals, shelters for the homeless and prisons, is currently recommended 59 because of the increased risk of transmission in these settings.…”

Section: Screening For Infectionmentioning

confidence: 99%

Tuberculosis Prevention

Bodarev¹

2008

International Encyclopedia of Public Health

View full text Add to dashboard Cite

“…However, the TST is not specific, and its interpretation is often difficult in individuals vaccinated with Mycobacterium bovis bacillus Calmette-Guérin (BCG) and in individuals who have been exposed to environmental mycobacteria (9). In addition, patients on immunosuppressive therapy and those who are HIV infected or have cancer have a diminished TST response (10). Furthermore, the cut-off value of the TST changes according to the tuberculosis prevalence, BCG coverage and nontuberculosis mycobacteria exposure (11,12).…”

mentioning

confidence: 99%